Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

April 25, 2011 09:01 ET

Allezoe Medical Holdings: Organ Transport Systems, Inc. (OTS) Attends Presentations at International Medical Conference and Holds Meetings Relating to Its Donor Organ Preservation Strategies

FRISCO, TEXAS--(Marketwire - April 25, 2011) -

Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announces that personnel from its wholly-owned subsidiary, Organ Transport Systems, Inc. ("OTS"), including Dr. Thomas D. Franklin, Jr., Ph.D., Executive Vice President of Research and Regulatory Affairs, have returned to the company's corporate headquarters following a week of meetings during the International Society for Heart and Lung Transplantation ("ISHLT") conference in San Diego, California. They attended the recent ISHLT conference to meet with OTS' research collaborators, medical advisors, clinical trial steering committee members, as well as heart transplant surgeons interested in using the OTS LifeCradle® device in clinical trials planned to begin in 2012. The ISHLT conference included a poster presentation by OTS pre-clinical research collaborators from University of Texas Southwestern Medical Center ("UTSW") who presented one of their studies using the LifeCradle® prototype device.

On-going research continues at UTSW and Duke University Medical Center ("Duke") where the OTS LifeCradle® HR devices are being used in discarded human heart studies and pre-clinical, animal transplantation studies with non-heart beating donors for the purpose of extending the use of the technology beyond the routine preservation of beating donor hearts. Currently, the industry standard is for a cooler with ice to be used for transportation of these vital organs. OTS' technology, including its LifeCradle®, aims to preserve organs for a longer time, allowing for organs to be transported wherever they might be needed, and thereby addressing the immense gap between donated organs and organs actually transplanted in recipients.

At ISHLT, OTS met with a number of its European collaborators who plan to participate in the OTS European trials with the LifeCradle® targeted for clinical sites in Paris, France and Pamplona, Spain as well as other European sites. Over the past several years OTS has developed strong relationships with hospitals and research centers in Europe, as well as cardiac transplant leaders like Dr. Pascal Leprince and Dr. Gregorio Rabago. Additional meetings were held with basic research collaborators from The Netherlands and Australia in regard to donor organ perfusion solutions and preservation technologies.

OTS also held meetings with individual heart transplant surgeons from leading US transplant centers that plan to participate in the US clinical trials at their request, to present updates of the pre-clinical research results with the OTS LifeCradle® and the proposed clinical trial protocols for Europe and the USA.

Dr. Franklin says, "Our team received consistently positive feedback about the LifeCradle® from the transplant community we met with. Whether they were commenting upon the ease of using the OTS LifeCradle® in the actual donor operating room setting, the fact that no additional personnel are required to utilize the LifeCradle®, the expected low user costs, or the potential of making more hearts available for transplantation, the uniform praise continues to fuel our motivation to move forward."

Dr. Bob Kormos from University of Pittsburgh Medical Center, ("UPMC"), a member of OTS' Medical Advisory Board, emphasized, "The OTS technology is the best documented and scientifically tested technology for donor heart preservation to date."

Dr. Franklin says, "We are deeply involved in the transplant community precisely so that OTS products, including the LifeCradle®, can continue to be market-driven products that will have long-term appeal. The ISHLT conference was further indication that we are scientifically doing all the right things while addressing what the medical community will care about most when making their decisions about what organ preservation technology to use."


This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company.

Contact Information